Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: Results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial

Journal of Gastroenterology

Volumn 47, Issue 5, 2012, Pages 540-552

  Sugano, Kentaro ^a   Kontani, Teiji ^b   Katsuo, Shinichi ^c   Takei, Yoshinori ^d   Sakaki, Nobuhiro ^e   Ashida, Kiyoshi ^f   Mizokami, Yuji ^g   Asaka, Masahiro ^h   Matsui, Shigeyuki ⁱ   Kanto, Tatsuya ^j   Soen, Satoshi ^k   Takeuchi, Tsutomu ^l   Hiraishi, Hideyuki ^m   Hiramatsu, Naoki ^j  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Komatsu Municipal Hospital   (Japan)

^c National Hospital Organization   (Japan)

^d Izumino Hospital   (Japan)

^e Foundation for Detection of Early Gastric Cancer   (Japan)

^f SAISEIKAI NAKATSU HOSPITAL   (Japan)

^g UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^l KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m DOKKYO MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Active controlled trial; Gastric or duodenal ulcers; Lansoprazole; Non steroidal anti inflammatory drugs; Osteoarthritis; Prevention; Rheumatoid arthritis

Indexed keywords

GEFARNATE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BACKACHE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DUODENITIS; DUODENUM ULCER; ECZEMA; FALLING; FEMALE; FOLLOW UP; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM EXPOSURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; OVARY TUMOR; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REFLUX ESOPHAGITIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STOMACH ULCER; TINEA PEDIS; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS; DOUBLE-BLIND METHOD; DUODENAL ULCER; FEMALE; GEFARNATE; HUMANS; KAPLAN-MEIER ESTIMATE; LOW BACK PAIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; STOMACH ULCER; TREATMENT OUTCOME;

EID: 84862518762     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0541-z     Document Type: Article

References (28)

1. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-96.
2. Bellary SV, Isaacs PE, Lee FI. Upper gastrointestinal lesions in elderly patients presenting for endoscopy: relevance of NSAID usage. Am J Gastroenterol. 1991;86:961-4.
3. Fries JF, Williams CA, Bloch DA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-22.
4. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103:2890-907.
5. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: omeprazole versus misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338: 727-34. (Pubitemid 28115091)
6. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, Van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: acid suppression trial: ranitidine versus omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719-26.
7. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169-75. (Pubitemid 34098186)
8. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91:223-7. (Pubitemid 126734008)
9. Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users\a randomized trial. Aliment Pharmacol Ther. 2003;18: 829-36. (Pubitemid 37323649)
10. Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM study. J Clin Biochem Nutr. 2007;40:148-55.
11. Regula J, Butruk E, Dekkers CP, de Boer SY, Raps D, Terjung A, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole vs. omeprazole. Am J Gastroen-terol. 2006;101:1747-55. (Pubitemid 44166581)
12. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011;46: 724-35.
13. Lanza FL, Royer GL, Nelson RS, Chen TT, Seckman CE, Rack MF. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol. 1981;75:17-21. (Pubitemid 11106121)
14. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia\a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther. 2005;21: 1055-61. (Pubitemid 40646530)
15. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991;115:195-200.
16. Kinjo M, Mishimura G. Fluorescence correlation spectroscopy as a detection tool of point mutation in gene. Bioimaging. 1997;5:134-8. (Pubitemid 27431721)
17. Zhang T, O'Keefe SJ, Winter T, Marks IN, Ogden J. Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-a, bFGF, and EGF receptor expression in humans. Dig Dis Sci. 1998;43:2764-70. (Pubitemid 29034934)
18. Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, et al. Helicobacter pylori infection and gastric neo-plasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol. 1998;93:1271-6. (Pubitemid 29076926)
19. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15: 1-20.
20. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet. 2008;372:392-7.
21. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-73. (Pubitemid 32240315)
22. Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang N, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gas-troenterol. 2002;97:2208-14.
23. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411-8. (Pubitemid 40874157)
24. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut. 1998;42:338-43. (Pubitemid 28197021)
25. Nakajima S, Nishiyama Y, Yamaoka M, Yasuoka T, Cho E. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J Gastroenterol Hepatol. 2010;25(Suppl 1):S99-110.
26. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-27.
27. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-53. (Pubitemid 46021498)
28. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroen-terol. 2010;16:2323-30.